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To understand cancer progression, it is desirable to study the earliest stages of its development, which are often microscopic
lesions. Array comparative genomic hybridization (aCGH) is a valuable high-throughput molecular approach for discovering
DNA copy number changes; however, it requires a relatively large amount of DNA, which is diﬃcult to obtain from microdissected
lesions. Whole genome ampliﬁcation (WGA) methods were developed to increase DNA quantity; however their reproducibility,
ﬁdelity, and suitability for formalin-ﬁxed paraﬃn-embedded (FFPE) samples are questioned. Using aCGH analysis, we compared
two widely used approaches for WGA: single cell comparative genomic hybridization protocol (SCOMP) and degenerate
oligonucleotide primed PCR (DOP-PCR). Cancer cell line and microdissected FFPE breast cancer DNA samples were ampliﬁed
by the two WGA methods and subjected to aCGH. The genomic proﬁles of ampliﬁed DNA were compared with those of non-
ampliﬁed controls by four analytic methods and validated by quantitative PCR (Q-PCR). We found that SCOMP-ampliﬁed
samples had close similarity to non-ampliﬁed controls with concordance rates close to those of reference tests, while DOP-
ampliﬁed samples had a statistically signiﬁcant amount of changes. SCOMP is able to amplify small amounts of DNA extracted
from FFPE samples and provides quality of aCGH data similar to non-ampliﬁed samples.
1.Introduction
Early breast cancer detection, accurate diagnosis, and per-
sonalized therapies have become goals of clinical medicine in
thegenomicera,andinthelastfewdecadesmoleculargenet-
ics advances have contributed greatly to the development of
those goals. The ability to identify genomic characteristics,
determine copy number variations, or measure RNA and
miRNA with a variety of technologies provided the medical
ﬁeld with tools to explore the molecular make up of any
sample and compare physiologic and pathologic states from
any human tissue. However, the accuracy of such techniques
depends largely on the purity of the samples provided for
analysis. At the same time, a relatively large amount of
nucleic acid is required for accurate results. Microdissection
techniques have increased the purity of samples, enabled
us to study the earliest stages of disease development, and
allow separation of diﬀerent tissue constituents, for example,2 ISRN Oncology
separating epithelial tissue from the surrounding stroma in
a breast lesion. A consequence of increased targeting ability
is a corresponding decrease in the amount of nucleic acid
available for research. In the breast cancer research ﬁeld,
examples of areas that deal with small lesions and limited
samples are the study of breast carcinoma in situ which is
a presumed precursor to invasive breast carcinoma and a
growing clinical problem [1, 2] and establishing the role of
the stroma or myoepithelial cells in the development of pre-
invasiveandinvasivelesions.Somebreastlesionslikeatypical
ductal hyperplasia and ﬂat epithelial atypia are of much
interest to pathologists and clinicians as they are upgraded to
carcinoma about 10–20% of the time in subsequent studies;
however opportunities to study such lesions are limited
because they are often discovered incidentally in biopsies,
and therefore the amount of samples available for research
is very small.
In breast cancer research, correlation of molecular char-
acteristics with outcomes helps identify predictive and prog-
nostic variables that are of great value in clinical practice,
unfortunately, most of the time that information can only be
obtained after lengthy periods of followup to record whether
or not the outcome of interest develops. This issue makes
ﬁnding prognostic and predictive markers very costly and
timeconsuming.Conversely,therearemillionsofFFPEsam-
ples worldwide, many associated with detailed clinical data
that makes them a precious resource for survival studies and
prognostic and predictive marker development. Therefore,
technologies that can be used on FFPE tissues without being
limited by the amount of sample are very valuable.
Array CGH (aCGH) is being widely used to identify the
areas of genomic gain and loss that occur in diﬀerent types
of lesions and oﬀers high-throughput capability, high res-
olution, and precise mapping of aberrations [3–6]. Several
microarray platforms have been developed and used for
aCGH including cDNA arrays [7–9], oligonucleotide arrays
[10, 11], BAC arrays [12–17], and most recently SNP arrays
[18–21].Unfortunately,inordertobeusefulinthemolecular
pathology lab, this type of molecular analysis requires an
abundant supply of high-quality genomic DNA from clinical
specimens, not only for the array CGH analysis but also to
validate results using an independent technique such as Q-
PCR.
To facilitate molecular analysis of small specimens, sev-
e r a lm e t h o d so fw h o l eg e n o m ea m p l i ﬁ c a t i o nh a v eb e e n
developed [22]. A commonly used method is degenerate
oligonucleotide primed PCR (DOP-PCR) [23]. DOP-PCR
has been modiﬁed and used for several diﬀerent types of
molecular analysis including chromosomal CGH [24–28],
high-resolution (HR-) CGH [29, 30], genotyping [31, 32],
LOH analysis [33], mutation detection [34], array CGH [35–
37] and more recently for methylation proﬁling of trace
amounts of DNA [38, 39]. Although DOP-PCR has been
widely accepted as a method of whole genome ampliﬁcation,
it is known that it introduces ampliﬁcation bias. While some
have been successful using DOP-PCR on FFPE tissues [40],
others have found that DOP-PCR is not well suited for
archived specimen analysis [41]. Artifactual ampliﬁcation at
chromosomes 1p, 3, 13q, and 16p as well as preferential
ampliﬁcation of shorter alleles [37]h a sb e e nr e p o rt e d .G r a n t
et al. consider DOP-PCR a useful ampliﬁcation method if
researchers monitor carefully storage conditions and accept
a “modest increase” in genotyping error [42]. Multiple
displacement ampliﬁcation (MDA) [43] and modiﬁcations
of MDA such as restriction- and circularization-aided rolling
circle ampliﬁcation (RCA-RCA) [44] and MDA using the
large fragment of Bst DNA polymerase [45]h a v eb e e n
used on FFPE tissue as a method of WGA for aCGH [46–
48]. The disadvantage of these methods, which employ a
polymerase, is that they may not perform well with degraded
DNAextractedfromFFPEtissues[46],andtheeﬃciencyand
accuracyofMDAvarywiththecelltype[49].Arecentreview
on the MDA method using nonﬁxed samples reports that it
introduced pronounced skewing when evaluating ribosomal
RNA [50]. To deal with MDA bias, some have suggested
combining two MDA reactions, one denatured and one
nondenatured, aiding copy number analysis and subsequent
genotyping [51].
The methods based on producing representative ampli-
consbyligation-mediatedPCR(LM-PCR)[52,53],balanced
PCR ampliﬁcation, and adaptor-ligation PCR of randomly
sheared genomic DNA (PRSG) have all performed well
for array CGH [44, 54, 55] where the random-primed
ampliﬁcation (RPA) has been used successfully with FFPE
tissuesforarrayCGHandfoundtobesuperiortodegenerate
oligonucleotide-primed ampliﬁcation for array-based CGH
[56].
Other technologies recently marketed for whole genome
ampliﬁcation include a linker-adapted PCR-based propri-
etary kit that was shown to be superior to MDA, DOP-
PCR, random priming, and RCA-RCA methods for FFPE
samples [57], OmniPlex which reports good results on WGA
ofFFPEtissuepriortoSNPanalysis[58]andrepli-Gwhichis
marketed as a WGA kit that uses the previously known Phi29
DNA polymerase method and adds a ligation step prior to
ampliﬁcation [27].
In 1999, Klein et al. published a ligation-mediated meth-
od of whole genome ampliﬁcation paired with chromosomal
CGH that was speciﬁcally designed for the analysis of gen-
omes of single cells and was termed “SCOMP” (single-cell
comparative genomic hybridization) [59].This method has
been used successfully for CGH analysis of FFPE specimens
[41,60]andforCGHanalysisofsinglecells[61,62].SCOMP
was found to be superior to DOP-PCR for global ampliﬁ-
cation of very small amounts of DNA from microdissected
FFPE samples [41].
While several groups have demonstrated that it is pos-
sible to perform WGA on FFPE samples, few have critically
assessed the resulting DNA for reproducibility and ﬁdelity of
replication on a genome-wide scale. We have tested several
methodsofWGA,systematicallyanalyzedtheirperformance,
and selected the two best performing, SCOMP and DOP-
PCR, for further assessment. The degree of WGA eﬀect
on identiﬁcation of genomic alterations was quantiﬁed and
compared between the methods. This assessment is a nec-
essary validation step of WGA methods and, we believe,
provides invaluable information for scientists using FFPE
samples for aCGH studies.ISRN Oncology 3
1.1. Samples and DNA Extraction. 20μg of genomic DNA
from the UACC-812 breast cancer cell line (ATCC, http://
www.atcc.org/) was extracted using the QIAmp DNA Mini
Kit (Qiagen, Canada) according to the manufacturer’s
instructions.DNAfromthecelllineandhumanplacentawas
digestedwith2.5UeachofRsaIandAluIrestrictionenzymes
(Invitrogen) in a ﬁnal volume of 100μL. The digested DNA
ranging in size from 100 to 10,000 base pairs was cleaned
using the Qiaquick PCR Puriﬁcation Kit (Qiagen, Canada)
and quantitated using a DyNA Quant Fluorometer (Amer-
sham Biosciences).
For FFPE samples, multiple 5μm thick sections of paraf-
ﬁn blocks were deparaﬃnized and stained for 30sec in hae-
matoxylin prior to microdissection. Tumor areas were iso-
lated in a dissecting stereo microscope using 18 G needles
and H&E-stained slides for guidance (under supervision of a
pathologist, S. J. Done). Microdissected tissue was incubated
in lysis buﬀer for 72hr, and DNA was extracted using the
QIAmp DNA Mini Kit.
1.2. DOP-PCR. Degenerate oligonucleotide primed (DOP-)
PCR was performed by two methods. First, using the DOP-
PCR Master Kit (Roche) according to the manufacturer’s
instructions; second, according to the protocol of Huang et
al. [27]. Brieﬂy, 10–100ng of genomic DNA was ampliﬁed
by Thermo Sequenase (Amersham Biosciences) in a low-
stringency preampliﬁcation step (5 cycles), followed by reg-
ular PCR ampliﬁcation in less stringent conditions. The
fragments generated by both methods ranged from 100 to
1000basepairs.Forbothmethods,severalreplicatereactions
were pooled together (n = 5–7 based on the sample size,
i.e, amount of material available) and a negative control
(template: water) was used to ensure absence of contami-
nation. The resulting ampliﬁed DNA was puriﬁed using the
Qiaquick PCR Puriﬁcation Kit (Qiagen, Canada) and quan-
tiﬁed using a DyNA Quant Fluorometer (Amersham Bio-
sciences).
1.3.SCOMP. TheinitialstepsoftheSCOMPprocedurewere
performed according to the protocol provided by Dr. Klein,
starting with 30–150ng of template DNA. Genomic DNA
was digested with 2U MseI (New England Biolabs) for 3
hours in One-Phor-All Buﬀer (Amersham) in a ﬁnal vol-
ume of 5μL. Base pairing of the adaptor nucleotides
was done in a ﬁnal volume of 3μL using 0.5μLO n e -
Phor-All Buﬀer, 0.5μ 100μML i b 1o l i g o n u c l e o t i d e( 5  -
AGTGGGATTCCTGCTGTCAGT-3 ), and 0.5μL 100μM
ddMse11 oligonucleotide (5 -TAACTGACAGCdd-3 )i na
MJResearchPT100thermocyclerprogrammedforagradient
of 65◦Ct o1 5 ◦Cr a m p e dd o w na t1 ◦Cp e rm i n u t e .1μLT 4
D N AL i g a s e( 4 0 U / μL) (Roche), 1μLo f1 0 m MA T Pa n d
the MseI digested genomic DNA was added and allowed
to incubate at 15◦C overnight. For PCR ampliﬁcation the
following was added to the ligation mix: 3μLE x p a n d
Long Template buﬀer 1 (Roche), 2μL1 0m Md N T P s ,3 5μL
H2Oa n d1 μL Expand-Long-Template PolMix (3.5U/μL).
Thermocycler conditions were as follows: 1 cycle, 68◦Cf o r
3mins;15cycles40secat94 ◦C,30secat57◦C,1min30sec+
1sec/cycleat68 ◦C; 8 cycles 40sec at 94◦C, 30sec at 57◦C+
1◦C/cycle, 1min 45sec + 1sec/cycle at 68◦C; 22 cycles
40sec at 94◦C, 30sec at 65◦C, 1min 53sec + 1sec/cycle at
68◦C; 1 cycle 3min 40sec at 68◦C. Several reactions were
pooled together (n = 5–7 as above). A negative control
(template:water)wasusedforallstepstoensuretherewasno
contamination. Following PCR ampliﬁcation, the resulting
products were cleaned with the Qiaquick PCR Puriﬁcation
Kit (Qiagen, Canada) and quantitated using a DyNA Quant
Fluorometer (Amersham Biosciences).
1.4. Array CGH. 2-3μgo fD N Aw a sl a b e l l e db yr a n d o m
priming (Bioprime DNA labeling Kit, Invitrogen) in 3
separate reactions with either Cy3 or Cy5. Labeled products
were mixed in appropriate combinations in DIG Easy
Hyb (Roche) hybridization buﬀer and hybridized for 16–
2 4h o u r sa t3 7 ◦C in a humidiﬁed chamber in duplicate
to the Human 19K single-spot cDNA arrays from the
ClinicalGenomicsCentre,UHN(UniversityHealthNetwork
Microarray Centre, http://www.microarrays.ca/), which con-
tain 19,008 human ESTs/genes with map positions identiﬁed
for ∼11,000 cDNA clones with the median distance between
mapped positions 73.4 Kb, where 93% of the clones spaced
<1Mb and 99% <3Mb. Slides were rinsed and then washed 3
times and centrifuged to dry.
Arrays were scanned using the GenePix 4000A scanner
(AxonInstruments,USA).Thephotomultipliergainforeach
laser was adjusted to give an average ratio of Cy3 to Cy5 of
1 and to minimize the number of saturated pixels. Images
were then analyzed using the GenePix Pro 3.0 software
(Axon Instruments, USA). Each subgrid on each array was
independently normalized by equalizing the Cy3 intensities
with respect to the Cy5 intensities, while excluding spots
ﬂagged as anomalous or absent by the quantifying software.
Log2 ratios were assigned to each spot and the proﬁles were
centered by the median value and scale normalized by the
median of absolute values.
1.5. Quantitative Real-Time (Q-RT) PCR. Primers were
designed using the Primer Express software (Applied Biosys-
tems). PCR was performed according to the ABI7700
protocolsusingtheQuantitectSYBRGreenPCRKit(Qiagen,
Canada). All PCR reactions were done in triplicate. DNA
from normal placenta was used as reference and relative gene
quantity was calculated by the delta-delta Ct method.
1.6. aCGH Analysis. First, we tested WGA methods using
higher-qualityDNAfromtheUACC-812celllineandhuman
placenta. Three independent runs of DNA from the cell line
ampliﬁed by SCOMP and DOP methods were compared
by correlation with nonampliﬁed controls (Pearson). Since
SCOMP was giving consistently better results, an additional
ﬁve samples ampliﬁed by this technique were tested. The
data was summarized by a pseudocolor matrix generated
using the Matlab R12 (MathWorks Inc, Natick, MA, USA)
software to display pair-wise correlations among individual
samples (Figure 1). Signiﬁcance analysis of microarrays
(SAM; http://www-stat.stanford.edu/∼tibs/SAM/)[ 63]w a s4 ISRN Oncology
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Figure1:Pseudocolorrepresentationofacorrelationmatrix,show-
ing a relationship between nonampliﬁed DNA (n = 8), SCOMP
(SCOMP ampliﬁed, n = 8), placenta (self-hybridizations of normal
genomic DNA, n = 8), and DOP (DOP-PCR ampliﬁed, n =
3) array experiments. The color map corresponds to the scale of
correlation coeﬃcients; positive correlated data range in color from
light blue to dark red, negatively correlated data range from light
blue to dark blue. The diagonal of the symmetric correlation matrix
represents self-correlation and thus is equal to one (dark red).
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Figure 2: Examples of genomic alterations identiﬁed in UACC-812
cells: gains on 1q, 8q, 17q and losses on 1p and 17p. Note that
SCOMP ampliﬁed samples have proﬁles almost identical to each
other and to nonampliﬁed control DNA.
used to identify signiﬁcantly ampliﬁed or deleted genes
among the ampliﬁed and nonampliﬁed datasets. A bina-
ry tree-structured vector quantization (BTSVQ; available
at http://www.cs.toronto.edu/∼juris/btsvq/downloads.html)
algorithmwasusedforunsupervisedclusteranalysis.BTSVQ
combinesapartitive k-meansclustering andaselforganizing
maps (SOMs) algorithm in a complementary way, to achieve
clustering of both samples and genes. A moving average of
microarray data (sliding window of 20 data points, Figure 2)
was used to search for genomic alterations previously report-
ed in UACC-812 cells.
Our next step was to test WGA methods on FFPE mi-
crodissected breast cancer samples. Initially, three samples
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Figure 3:ExampleofaCGHanalysisofFFPEbreastcancersamples.
Chromosomes 17 (upper panel) and 7 (lower panel) analyzed by
moving average (upper graphs of both Ch17 and Ch7 panels)
and segmentation (lower graphs). Ch17 of this sample showed
ampliﬁcations at 17q12-21 centered at the HER2/neu gene, a broad
region of gain on distal 17q, three regions of gain and one region
of loss on 7q. SCOMP ampliﬁed samples resolved all segments
and peaks identiﬁed in nonampliﬁed control DNA, while DOP
ampliﬁed samples had signiﬁcant alterations of the proﬁles.
wereampliﬁedbySCOMPandDOPmethods andcompared
to nonampliﬁed controls. Then, since SCOMP performed
better, three additional samples ampliﬁed by SCOMP were
added to the analysis. All proﬁles were analyzed by Pearsons
correlation of nonsegmented aCGH data between ampliﬁed
samples and corresponding nonampliﬁed controls. We also
counted the number of individual cDNA spots concordant
as gain or loss between the test and corresponding control
s a m p l e sa sw e l la sb e t w e e nt h ed u p l i c a t er u n so fn o n a m p l i -
ﬁed control DNA. Additionally, the proﬁles were analyzed as
whole genomes by arranging clones in the genomic sequence
(National Center for Biotechnology Information, build 201
and University of California, Santa Cruz, build hg18) and
identifying genomic alterations by the circular binary seg-
mentation algorithm (“DNAcopy” package ver. 2.5.0 for “R”
ver. 2.5.0, http://www.r-project.org/) and peaks of moving
average (Figure 3). Duplicate runs of nonampliﬁed control
samples were used to establish reference values for each type
of analysis.
The segmentation algorithm was used to identify con-
tiguous segments of statistically uniform individual data
points. The segments of ampliﬁed samples and the segments
of nonampliﬁed controls were screened to identify regions
of overlapping concordant gains and losses. The lengths of
the concordant regions were summed, and the percentage
of concordantly identiﬁed genome length was calculated for
each ampliﬁed sample. Then, peaks of genomic alterations
were visualized by moving average as described above,
and the peaks of ampliﬁed samples of the same sign andISRN Oncology 5
position as the peaks of control samples were recorded as
concordant without restrictions for amplitude. All other
peaks were recorded as discordant. Percentages of concor-
dant/discordant peaks were calculated per ampliﬁed sample.
1.7. WGA. We have evaluated four major PCR-based meth-
ods of WGA and investigated their suitability for processing
FFPE clinical samples. The methods include two varia-
tions of DOP-PCR [23, 27], SCOMP [41, 59], and T7-
based linear ampliﬁcation of DNA (TLAD) [64]. We did
not investigate methods based on multiple displacement
ampliﬁcation (MDA) using DNA polymerase [43, 45, 46],
because the enzyme may not be suitable for FFPE clinical
samples due to fragmentation of the template genomic
DNA [46]. Our preliminary tests eliminated two of the four
methods. The DOP-PCR Master Kit (Roche, Mannheim,
Germany) performed well with good-quality genomic DNA
from our cell line, however, failed to amplify genomic DNA
extracted from FFPE tissue. In addition, it was often subject
to contamination in the negative control, which was of
signiﬁcant concern given the low quantities of genomic DNA
we expected to use (as low as 10ng). The TLAD protocol
was laborious and costly, and there was signiﬁcant loss of
template DNA in the initial steps due to many puriﬁcation
steps. Although TLAD did signiﬁcantly amplify the amount
of starting material up to 100x in our hands, the CGH arrays
failed due to what appeared to be poor labeling eﬃciency of
the resulting products. The remaining DOP-PCR protocol
and SCOMP performed well during preliminary tests and
were further analyzed by aCGH.
Both modiﬁed DOP-PCR and SCOMP performed
equally well at amplifying genomic DNA from cell lines as
well as from FFPE material. Starting with as little as 10ng of
g e n o m i cD N A ,w ew e r ea b l et og e ta sm u c ha s2 - 3μgf r o m
the modiﬁed DOP-PCR protocol and SCOMP with products
ranging in size from 10 to 10,000bp, and 100 to 1,500bp
respectively. The negative controls (template: water) in both
cases showed little or no product formation. When product
formation was detected in the negative control lane, the
products from that experiment were not used for analysis.
1.8. DNA from Cell Line and Placenta. UACC-812 cell line
wasusedasasourceofhigh-qualityDNA.Thecellshavebeen
shown to harbor several regions of ampliﬁcation including
1q, 8q, 13q, 17q, and 20q [65] and ampliﬁcation of the DNA
topoisomerase II (TOP2) gene [66]. Our aCGH proﬁles of
control samples showed alterations of the expected regions,
including those on chromosomes 1, 8, and 17 shown in
Figure 2.
To validate the microarray data by an independent
molecular method, we performed Q-PCR on 15 genes found
to be ampliﬁed by corresponding cDNA clones in ampliﬁed
or nonampliﬁed material, as well as 7 random genes. The
relative ratio of UACC-812 to placenta was calculated for
cDNA clones of aCGH and compared to relative gene quan-
titydeterminedbyQ-PCR.FornonampliﬁedDNA,loss/gain
was conﬁrmed in 18 out of 22 samples with correlation of
absolute values r = 0.62 (Pearson), for SCOMP-ampliﬁed in
19/22 (r = 0.75), and 9/22 (r = 0.22) in the DOP-ampliﬁed
experiments (Table 1).
Initially, we tested and compared DOP and SCOMP
methods using three samples in a group and then expanded
the number of SCOMP ampliﬁed samples to further test
the technique as it showed greater ﬁdelity. Figure 1 shows
pair-wise correlations between aCGH proﬁles. The highest
reproducibility was observed for nonampliﬁed samples.
SCOMP-ampliﬁed samples showed higher correlation with
the nonampliﬁed controls than DOP-ampliﬁed samples. As
expected, the self/self hybridizations of DNA from placenta
correlated well with each other and did not correlate with
the nonampliﬁed, SCOMP-ampliﬁed, or DOP-ampliﬁed
DNA from UACC-812 cells. The DOP-ampliﬁed samples
had the lowest correlation between each other and with the
control samples.
1.9. FFPE Samples. First, both WGA methods were com-
pared using three samples of microdissected breast cancer.
Although nonsegmented proﬁles of both WGA methods
showed similar correlation with corresponding controls
(Table 2), there was a trend for a greater number of
concordant spots within the SCOMP samples. The mean
percentage of cDNA spots concordant with the controls for
gain/loss assignment was 65.7, 68.5, and 71.7% for DOP,
SCOMP, and reference duplicate control runs, respectively,
where diﬀerence between the groups was not statistically
signiﬁcant. Among the cDNA clones assigned discordantly
opposite to the controls as gain or loss, there were clones
discordant recurrently in all samples within the groups
of SCOMP, DOP, or duplicate control samples: 2.53, 1.56
and 1.61%, respectively (diﬀerence not signiﬁcant). The
diﬀerence with the Log2 values of the control or duplicate
runs was similar between the groups: 0.25, 0.26, and 0.21,
respectively (diﬀerence not signiﬁcant). These recurrent
spots were diﬀerent within each group.
Since the purpose of aCGH is identiﬁcation of regions
of genomic gain or loss rather than values of individual
cDNA clones, we aimed to assess regions of gains/losses
identiﬁed by segmentation and moving averages (Figure 3).
The median number of segments per sample was similar
between the groups: 41, 40, 41, 37 for all, control, SCOMP,
and DOP samples, respectively, where the median number
of segments of gain was 20, 25, 20, 20, and segments of loss
20, 15, 21, 17. There was 42.5% genome length concordance
between segments identiﬁed in DOP and corresponding
nonampliﬁed controls, which were signiﬁcantly lower than
the 78.6% reference length concordance (reference: duplicate
runs of nonampliﬁed samples, P<0.01, Mann-Whitney).
ForthesameFFPEsamples,SCOMP-ampliﬁedDNAshowed
segmentation patterns similar to the nonampliﬁed controls
withaconcordancerateof68.5%,whichwasnotsigniﬁcantly
diﬀerent from the reference runs (Table 2). A similar advan-
tage of the SCOMP method was observed by comparing
peaks of genomic alterations: SCOMP samples had 84.4%
concordant peaks compared to 72.2% of DOP-ampliﬁed
samples, where the latter was signiﬁcantly lower than the
reference concordance rate.6 ISRN Oncology
Table 1: Quantitative real-time PCR results compared with array CGH.
cDNA clone Gene Location Gene relative quantity by Q-PCR Copy number by aCGH
Control SCOMP DOP
H17813 TOP2A 17q21 5.86 ++ +++ N
H59203 CDC6 17q21.3 2.87 +++ ++++ N
H23044 TEM7 17q21.1 2.45 ++ +++ +
H64260 PRKAG2 7q35 2.23 N N N
H18802 Link-GEFII 17q21.1 2.19 ++++ ++++ +
H46384 PRO2521 17q21.1 2.18 ++++ ++ N
T85025 1.97 ++++ ++++ N
H29706 GPC5 13q32 1.79 +++ ++++ N
H59714 AK2 1p34 1.58 ++ +++ N
321749 1.55 + +++ N
H20867 PCDH9 13q14.3 1.46 +++ ++++ N
H93272 CPM 12q15 1.42 + + N
AA011584 1.38 + ++ +
W24419 1.36 +++ + N
H85791 1.32 + + + +
H01255 CLN5 13q21.1 1.22 +++ ++ +
H62028 DYRK3 1q32 1.18 + + +
H14685 PTK2 8q24 1.06 N N N
R06520 PRKCBP1 20q13.12 0.98 N N N
R24935 CDA08 16q11.2 0.76 − NN
H46055 KIAA0725 8p11.21 0.75 + N N
H53288 BAG4 8p11.21 0.71 N N N
“−” Ratio less than 0.7, N = 0.7 −1.3, “+” ratio greater than 1.3.
“++” Ratio greater than 2, “+++” ratio greater than 3, “++++” Ratio greater than 5.
Table 2: Assessment of ﬁdelity of WGA of DNA extracted from breast cancer FFPE tissue. Ampliﬁcation was performed by two methods:
DOP and SCOMP. aCGH proﬁles of pre- (control) and post-ampliﬁcation DNA samples were compared by correlation of raw aCGH data,
segmentation and peaks of genomic alterations (means of three independent experiments).
DOP versus
control
SCOMP versus
control
SCOMP versus
control∗ Control repeats
Correlation of nonsegmented proﬁles (Pearson) r = 0.41 (<0.01) r = 0.47 (<0.01) r = 0.43 (<0.01) r = 0.72
Gain/loss concordance of segmentation (% of genome length) 42.5% (<0.01) 68.5% (N/S) 67.8% (N/S) 78.6%
Peaks of ampliﬁed samples concordant to controls (% of all peaks) 72.2% (<0.01) 84.0% (N/S) 84.4% (N/S) 94.2%
Third column (∗) represents the extended set of 6 SCOMP ampliﬁed samples. P values in brackets are calculated for diﬀerence with control repeats by two-
tailed exact Mann-Whitney U test; N/S: not signiﬁcant.
To better assess the preferred WGA ampliﬁcation meth-
od, we added more samples to the SCOMP group. Overall,
67.8% of detected segments and 84.4% of peaks identiﬁed
in SCOMP ampliﬁed samples were concordant with those of
nonampliﬁed controls.
2. Discussion
Our aim was to compare and validate whole genome ampli-
ﬁcation methods for aCGH of microdissected FFPE tissue.
SCOMP was particularly promising because it has been suc-
cessfullyusedforanalysisofsingle cellsisolatedfromabreast
cancer cell line [59], disseminated tumour cells in minimal
residual cancer in the bone marrow [67], DNA extracted
from archival material [41], and circulating melanoma cells
[61]. In all cases there was low amount of genomic DNA
available for study. DOP-PCR on the other hand is a
well-established, technically straightforward method that is
widely accepted as a method of WGA. DOP-PCR-generated
DNA has been used for many applications, including aCGH
[68, 69]. In both of these publications genomic BAC arrays
were used, which have lower resolution than other aCGH
modalities. Previously, Stoecklein et al. [41] had shown that
SCOMP was preferable to DOP-PCR for use with formalin-
ﬁxed samples; however, it was only validated using chromo-
somal CGH. We compared the techniques and tested further
the better performing method by a high-resolution aCGH.
To initially test the methods, we used better-quality
DNA extracted from fresh samples and found SCOMP
superior to DOP-PCR (Figure 1). To validate the aCGHISRN Oncology 7
platform before further analysis, we used quantitative PCR
(Q-PCR) and tested 22 genes in the three groups of data—
nonampliﬁed, SCOMP-ampliﬁed, and DOP-ampliﬁed. The
highest agreement was in the nonampliﬁed and SCOMP-
ampliﬁed datasets (Table 1).
Ournextstepwastocomparethegenomicproﬁlesgener-
ated by aCGH. The proﬁles of the samples ampliﬁed by both
techniques had similar correlation with the controls; how-
ever, there was a trend for the DOP group to have a higher
percentage of discordant individual spots. Only a small
proportion of the discordant spots were observed repeatedly
within the samples of each group, which we interpreted as
indication of the artifacts being predominantly random and
not speciﬁc for cDNA clone sequence, spot position within
the array, or other factors speciﬁc for ampliﬁcation method
or the microarray platform. After reliability of the aCGH
platform and ampliﬁcation techniques were evaluated, we
proceeded to experiments with FFPE specimens. In these
experiments, aCGH analysis showed consistently better per-
formance of the SCOMP technique compared to DOP-PCR.
Since aCGH has been successfully used in breast cancer
research to characterize breast cancer cell lines and identify
regions of common genomic alterations in diﬀerent cancer
subtypes [65, 70], we used current approaches of aCGH
analysis to study the eﬀect of WGA on accurate detection of
alterations. The segmentation algorithm we used has been
successfullyemployedinmultipleaCGHstudies[71–73]and
is becoming a routine tool for denoising aCGH data from
clinical samples. Additionally, we complemented segmenta-
tion analysis by identifying peaks of genomic alterations. To
avoid biases we intentionally did not use cut-oﬀst oﬁ l t e r
segments or peaks by the degree of signiﬁcance. SCOMP
showed higher ﬁdelity and allowed identiﬁcation of the
genomic alterations detected in nonampliﬁed samples by
both segmentation and moving average analyses at rates
close to the reference values. The diﬀerence between median
rates of the SCOMP and the reference group was 11% and
10% for the segmentation and moving average analyses,
respectively. Although they may serve as estimates of arti-
facts introduced by SCOMP ampliﬁcation, the diﬀerences
were not statistically signiﬁcant. The DOP method showed
signiﬁcant alterations of the proﬁles introducing 36% and
22%ofdiscordantsegmentationandpeakidentiﬁcationover
the reference values (Table 2). Our concordance rates are
representative of the techniques, and the actual rates are
expected to vary with quality of samples and aCGH plat-
forms used. Combined, our results show that of the methods
testedSCOMPisthemostsuitablemethod forWGAofFFPE
tissues and delivers results similar to nonampliﬁed samples.
Understandingthegenomiccharacteristicsandevolution
of breast cancer lesions is a necessary step to answer many of
the questions posed in the clinical setting, including which
lesions are more likely to develop local recurrence or metas-
tasisandthereforewhowouldbeneﬁtfromadjuvanttherapy.
Unfortunately,thelesionsofinterestareusuallysmallandthe
availability of genomic DNA for research extremely limited.
Use of existing breast archival FFPE material is optimized
by microdissecting samples to obtain homogeneous histo-
logically deﬁned cell populations from small-volume lesions.
WGA cannot be avoided in these settings, and our data show
that SCOMP has the potential to be an invaluable tool for
breast cancer research.
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